Esther Oomen-de Hoop

19PUBLICATIONS
61CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)AllergyPacific Peoples theory of change models for healthCancer diagnosis
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (19)

|May 25, 2026
Sex Impacts Progression-Free Survival of Alectinib through Drug Exposure in Patients with ALK-Positive Non-Small Cell Lung Cancer.

|Dec 26, 2025
Clinical Safety of Extended Interval Dosing of Nivolumab in Patients with Melanoma.

Ruben Malmberg, Maaike M Hofman, Fatima Ashad

|Sep 04, 2025
Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer: circulating tumor DNA analysis of a randomized phase 3 trial.

Elisabeth M Jongbloed, Noor Wortelboer, Vanja de Weerd

|May 01, 2025
Semaglutide impairs bioavailability of alectinib: a note of warning based on a cross-over pharmacokinetic drug-drug interaction study.

Niels Heersche, Daan A C Lanser, Esther Oomen-de Hoop

|Apr 30, 2025
Improving Shared Decision-Making in Early Phase Clinical Trials and Palliative Care: A Prospective Study on the Impact of an Online Value Clarification Tool Intervention.

Liza G G van Lent, Julia C M van Weert, Maja J A de Jonge

|Jun 07, 2024
Effect of Switching the Histamine-1 Receptor Antagonist Clemastine to Cetirizine in Paclitaxel Premedication Regimens: The H1-Switch Study.

Ruben Malmberg, Leni van Doorn, Juul M Cox

Pageof 4

Frequent Collaborators

9 joint publications

Ron H J Mathijssen

4 joint publications

Carin C D van der Rijt

3 joint publications

Astrid A M van der Veldt

2 joint publications

Jorie Versmissen